You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023160018
Dec 20236008
Jan 20245304
Feb 20244801
Mar 20244800
Apr 20246603
May 20248807
Jun 20243806
Jul 20245805
Aug 20244603
Sep 20248204
Oct 202454012
Nov 20246407
Dec 20244006
Jan 202555012
Feb 2025404
Mar 2025001
Apr 2025001
May 2025006
Jun 2025006
Total9640114